Vanessa Coeli summarises the PRIDE study on the experiences of conversion practices and mental health symptoms in sexual and gender minority adults in the US.
[read the full story...]
Gemma Lewis and Glyn Lewis summarise a robust systematic review and meta-analysis investigating the incidence of symptoms when discontinuing or withdrawing from antidepressants. The data suggest that 8-14% of patients will experience antidepressant discontinuation symptoms, and for around 2% these symptoms will be severe.
[read the full story...]
John Baker reflects on a recent review on rates and risk factors of coercion in inpatient child and adolescent mental health services.
[read the full story...]
Pauline Rivart summarises a national cohort study of ethnicity and suicide in England and Wales, which presents a “paradoxical finding of a lower rate of suicide in almost all minority ethnic groups compared with the White British majority”.
[read the full story...]
Niamh Dooley explores a retrospective study of ‘real-world’ data on young people’s use of general practitioners for mental health support.
[read the full story...]
Derek de Beurs explores a meta-analysis which finds that randomised controlled trials of psychological interventions for depression rarely report assessments of suicide.
[read the full story...]
Helen Dodd summarises a recent non-inferiority randomised controlled trial led by Cathy Creswell, which investigated the effectiveness of digitally augmented parent-led CBT for child anxiety.
[read the full story...]
Roxanne Keynejad summarises the ESMI-II study on community perinatal mental health teams and mental health, obstetric and neonatal outcomes in pregnant women.
[read the full story...]
Matthias Schwannauer explores the BESST cluster randomised controlled trial, which is out today in The Lancet Psychiatry. BESST stands for Brief Educational Workshops in Secondary Schools Trial.
[read the full story...]
Samei Huda summarises a new network meta-analysis in the Lancet Psychiatry on the efficacy and effectiveness of antipsychotics for schizophrenia in research settings, such as randomised controlled trials, versus real-world and clinical settings.
[read the full story...]
